Crying Wolf?
Executive Summary
Today, drug companies are experiencing unprecedented success on precisely the terms that managed care should have denied it: robust pricing and profitability and a new definition of success for individual products, the mega-blockbuster. Aggressive direct-to-consumer ad campaigns and the success of new, so-called lifestyle or cosmetic drugs, such as {Viagra}, only underscore the impotence of managed care organizations in their efforts to rein-in pharmaceutifal costs. But there are rumblings in some corners of the industry that drug companies take managed care's impotence for granted at their peril.
You may also be interested in...
EU Commission Wants Expert Opinion On Prostaglandin Analogs In Eyelash Growth Cosmetics
The Scientific Committee on Consumer Safety will consider available safety data for prostaglandin analogs isopropyl cloprostenate, ethyl tafluprostamide and others with known use in eyelash-growth cosmetic products in the EU. Currently, the substances are not restricted in cosmetic products.
Thermo Fisher Scientific, Hillrom To Acquire Diagnostics Companies To Bolster Portfolios
Thermo Fisher Scientific has agreed to buy Mesa Biotech for $450m in cash and Hillrom will acquire Bardy Diagnostics for $375m in cash. Both deals will add complementary digital health solutions, which may be a continued trend in 2021.
Cosmetic And Personal Care Trademark Review 19 January, 2021
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Need a specific report? 1000+ reports available
Buy Reports